Biopharma | Ophthalmology Innovation Source

Circadian Technologies (Opthea)

Participant: Megan Baldwin Dr. Megan Baldwin is CEO/Managing Director of Circadian Technologies (Opthea) and has over 19 years of experience in preclinical and clinical development of therapies for cancer and eye diseases. View Full Profile

Iconic Therapeutics

Participant: William L. Greene, MD Dr. Greene has served as CEO of Iconic Therapeutics since 2014. He brings 20 years of experience as an operating executive, clinician, investor, and entrepreneur. View Full Profile

PanOptica

Participant: Paul Chaney Paul G. Chaney is Co-Founder, President & CEO of PanOptica Inc., a biopharma company developing PAN-90806, a novel topical anti-VEGF treatment for neovascular eye diseases. View Full Profile

Aerie Pharmaceuticals

Rhopressa is a Rho-kinase inhibitor that increases the outflow of the trabecular meshwork by relaxing it. It’s also a norepinephrine transport inhibitor that decreases the amount of fluid being produces, and drops episcleral venous pressure. Aerie has completed two phase III trials, with the Rocket 2 data being used to file the NDA for the…

Ophthotech Corporation

Fovista is an anti-platelet derived growth factor (PDGF) agent for wet age-related macular degeneration (AMD) combination therapy currently in phase 3 studies. Pending regulatory approval, Ophthotech will commercialize Fovista in the U.S., and has partnered with Novartis outside the U.S. in a deal worth more than $1 billion in upfront and potential milestone payments. The…

Alimera

Alimera Sciences is “dedicated to change the paradigm of how we think about and subsequently treat diabetic macular edema (DME),” Mr. Myers said. Iluvien is a fluocinolone (corticosteroid) implant for the treatment of DME. One implant releases 0.2 mcg per day, giving patients up to 3 years’ worth of therapy. Iluvien is “a real advancement…

Ophthalmic Innovation 2015 – “A View from the NEI”

Participant: Paul A. Sieving, MD, PhD Dr. Sieving became Director of the National Eye Institute after serving as the Paul R. Lichter Professor of Ophthalmic Genetics and founding director of the Center for Retinal and Macular Degeneration at the University of Michigan. View Full Profile

Masters of the Universe

Participants: Jim Mazzo James V. Mazzo is Global President for Carl Zeiss Meditec’s Strategic Business Unit Ophthalmic Devices, which includes Ophthalmic Diagnostics, Surgical Ophthalmology and Refractive Lasers. View Full Profile Jeff George Jeff was appointed to lead Alcon in May 2014. As the global leader in eye care, Alcon provides innovative products that enhance quality…

Mati Therapeutics

Mati is developing a punctal plug drug delivery technology for sustained drug delivery using an “L-shaped” design to deliver medications to the canalicular space. Insertion is via slit lamp, with only the initial procedure requiring patient dilation. The company’s device separates itself from others in that there is a one-directional drug flow out of the…

Saunders Speaks to Allergan’s Innovative Culture

Prior to the announcement of the Pfizer-Allergan combination, Allergan CEO and President Brent Saunders spoke with OISTV about how the pharma industry finds and foster innovation, particularly in ophthalmology. Under Saunders, Allergan works hard to “support” rather than “assimilate” new technologies like Oculeve’s neurostimulation-based treatment for Dry Eye. As President and COO of the new…

A Record-Setting OIS

Last week’s Ophthalmology Innovation Summit drew nearly 1,000 attendees to Las Vegas’ Planet Hollywood hotel, marking the largest OIS event we’ve held yet. The size of the audience only added to the energy of what’s becoming a kickoff tradition for the American Academy of Ophthalmology’s annual meeting. Three dozen ophthalmology companies – representing Drug Delivery,…

A Rundown of a Record-setting OIS

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 066″] The Ophthalmology Innovation Summit hit it big in Las Vegas prior to the industry’s American Academy of Ophthalmology Annual Meeting. With close to 1,000 registered attendees, OIS@AAO brought innovators together with both public and private investors as well as corpo-rate leaders of our dynamic sector. OIS Podcast walks through the…